MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 886 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
AKP-001
CAS:<p>AKP-001 is a selective inhibitor of MAPK of the p38α isoform and is used in the study of immune and digestive disorders.</p>Fórmula:C21H13ClF2N4O2Pureza:99.50% - 99.92%Forma y color:SolidPeso molecular:426.8SOS1-IN-15
CAS:<p>SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer.</p>Fórmula:C28H27F3N6O2Pureza:98.32%Forma y color:SolidPeso molecular:536.548NMDAR/TRPM4-IN-2
CAS:<p>Potent NMDAR/TRPM4-IN-2 blocks NMDAR/TRPM4, protects brain and retinal neurons, and prevents mitochondrial dysfunction with an IC50 of 2.1 μM.</p>Fórmula:C11H19BrCl2N2Pureza:98.77%Forma y color:SolidPeso molecular:330.092SOS1-IN-8
CAS:<p>SOS1-IN-8 is an inhibitor of SOS1 and acts on SOS1-G12D (IC50: 11.6 nM) and SOS1-G12V (IC50: 40.7 nM).</p>Fórmula:C24H26F3N3O4Forma y color:SolidPeso molecular:477.48RAF mutant-IN-1
CAS:<p>RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).</p>Fórmula:C23H18Cl3FN6O2SPureza:98%Forma y color:SolidPeso molecular:567.85ERK Inhibitor II (Negative control)
CAS:<p>ERK Inhibitor II, a control, blocks ERK and insulin receptor activation, aiding diabetes research.</p>Fórmula:C18H12N6OForma y color:SolidPeso molecular:328.33MS934
CAS:<p>MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.</p>Fórmula:C52H69F3IN7O6SPureza:98%Forma y color:SolidPeso molecular:1104.11AZD4747
CAS:<p>AZD4747 is an inhibitor of the mutant GTPase KRASG12C that hasial antitumor activity for the study of pancreatic and colorectal adenocarcinoma.</p>Fórmula:C24H22ClFN2O3Pureza:99.36%Forma y color:SolidPeso molecular:440.89p38-α MAPK-IN-1
CAS:<p>p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with IC50 of 2300 nM and 5500 nM in EFC displacement assay and HTRF assay,respectively.</p>Fórmula:C27H35N5O3Pureza:99.93%Forma y color:SolidPeso molecular:477.6KRAS G12C inhibitor 14
CAS:<p>KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor with an IC 50 of 18 nM [1].</p>Fórmula:C24H19ClF2N4O3Pureza:98%Forma y color:SolidPeso molecular:484.88L 731734
CAS:<p>L 731734 is a farnesyltransferase inhibitor.</p>Fórmula:C19H38N4O3SForma y color:SolidPeso molecular:402.6KRAS G12C inhibitor 30
CAS:<p>KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.</p>Fórmula:C25H22ClFN6O3Forma y color:SolidPeso molecular:508.93Pan-RAF kinase inhibitor 1
CAS:<p>Potent Pan-RAF inhibitor 1 targets RAF/MAPK pathway, curbing RAS-mutated cancer cell growth. (Patent WO2021110141A1, compound 16B)</p>Fórmula:C26H24F3N3O4Forma y color:SolidPeso molecular:499.48KRAS G12C mutant protein inhibitor A-1
CAS:<p>KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.</p>Fórmula:C31H26ClF4N7O2Forma y color:SolidPeso molecular:640.03KRAS G12C inhibitor 13
CAS:<p>KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .</p>Fórmula:C40H46F3N7O4Pureza:98%Forma y color:SolidPeso molecular:745.83RPR203494
CAS:<p>RPR203494 is a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.</p>Fórmula:C26H29FN6O4Forma y color:SolidPeso molecular:508.54HPK1-IN-37
CAS:<p>HPK1-IN-37 (compound A85), with an IC50 value of 3.7 nM, is a potent inhibitor of HPK1.</p>Fórmula:C27H35N7O4Forma y color:SolidPeso molecular:521.61PROTAC KRAS G12C degrader-3
CAS:<p>PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].</p>Fórmula:C63H75ClN14O6Pureza:98%Forma y color:SolidPeso molecular:1159.81ERK1/2 inhibitor 8
CAS:<p>ERK1/2 inhibitor 8 is a potent inhibitor of ERK that acts on ERK2 (IC50: 0.48 nM).</p>Fórmula:C23H20ClN7O2SForma y color:SolidPeso molecular:493.97SOS1-IN-4
CAS:<p>SOS1-IN-4 is a potent inhibitor of SOS1 (IC50: 56 nM) and can be used in the study of KRAS-C12C/SOS1 interactions.</p>Fórmula:C24H29F2N4O2PForma y color:SolidPeso molecular:474.48KRAS G12C inhibitor 35
CAS:<p>KRAS G12C inhibitor 35 targets KRAS G12C in cancer research (CN112920183A, compound 3).</p>Fórmula:C31H27ClF2N6O3Forma y color:SolidPeso molecular:605.03Deltasonamide 1
CAS:<p>Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.</p>Fórmula:C30H39ClN6O4S2Forma y color:SolidPeso molecular:647.25(aS)-PH-797804
CAS:<p>(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating inhibitory concentration (IC50) values of 26 nM for p38α and 102 nM for p38β. This compound exhibits anti-inflammatory activity [1] [2].</p>Fórmula:C22H19BrF2N2O3Forma y color:SolidPeso molecular:477.3AMG-548 hydrochloride (864249-60-5 free base)
<p>AMG-548 hydrochloride is an orally active and selective p38α inhibitor (Ki: 0.5 nM) and shows slightly selective over p38β (Ki: 36 nM) and >1000 fold selective</p>Fórmula:C29H28ClN5OPureza:98%Forma y color:SolidPeso molecular:498.02KRAS G12C inhibitor 41
CAS:<p>KRAS G12C inhibitor 41 targets a key signaling protein, potentially aiding cancer research.</p>Fórmula:C36H37ClFN9O2Forma y color:SolidPeso molecular:682.19KRAS inhibitor-14
CAS:<p>KRAS inhibitor-14 targets G12C (IC50: 0.249 μM) and inhibits p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancers.</p>Fórmula:C20H15Cl3FN3O2SForma y color:SolidPeso molecular:486.77JNK3 inhibitor-3
CAS:<p>JNK3 Inhibitor-3 selectively blocks JNK3 (>4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.</p>Fórmula:C26H25N7O2Pureza:98%Forma y color:SolidPeso molecular:467.52MEK-IN-6 hydrate
CAS:<p>MEK-IN-6 hydrate (compound 69), a MEK inhibitor, exhibits an IC50 value of 2 nM in A375 cells [1].</p>Fórmula:C18H22FN3O5SPureza:98%Forma y color:SolidPeso molecular:411.45MEK-IN-6
CAS:<p>MEK-IN-6 (Example 69), a potent MEK inhibitor, effectively inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells, with an IC50 of 2 nM, making it</p>Fórmula:C18H20FN3O4SPureza:98%Forma y color:SolidPeso molecular:393.43KRas G12C inhibitor 1
CAS:<p>KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.</p>Fórmula:C31H38N6O3Pureza:98%Forma y color:SolidPeso molecular:542.67TNIK&MAP4K4-IN-1
CAS:<p>TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor targeting TNIK and MAP4K4/HGK, exhibiting IC50 values of 1.29 nM and <10 nM, respectively, in human</p>Fórmula:C25H23FN4O3Forma y color:SolidPeso molecular:446.47KRAS G12C inhibitor 34
CAS:<p>KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.</p>Fórmula:C32H32ClN5O3Forma y color:SolidPeso molecular:570.08SOS1-IN-7
CAS:<p>SOS1-IN-7 (compound 18-p1) is a potent inhibitor of SOS1 and acts on SOS1-G12D (IC50: 20 nM) and SOS1-G12V (IC50: 67 nM).</p>Fórmula:C23H25F3N4O3Forma y color:SolidPeso molecular:462.46p38 Kinase inhibitor 4
CAS:<p>Compound 135, also known as p38 Kinase Inhibitor 4, is a potent inhibitor of p38 [1].</p>Fórmula:C12H9Cl2N3OPureza:98%Forma y color:SolidPeso molecular:282.13JNK3 inhibitor-1
CAS:<p>JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.</p>Fórmula:C21H17ClFN5O2SForma y color:SolidPeso molecular:457.91GGTI-297
CAS:<p>GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).</p>Fórmula:C26H31N3O3SForma y color:SolidPeso molecular:465.61KRAS G12C inhibitor 5
CAS:<p>KRAS G12C inhibitor 5 is a KRas G12C inhibitor.</p>Fórmula:C32H37N7O2Pureza:98%Forma y color:SolidPeso molecular:551.68SOS1-IN-14
CAS:<p>SOS1-IN-14 是选择性的、有效的、口服具有活力的 SOS1 抑制剂 (IC50: 3.9 nM)。SOS1-IN-14 能够利用 P-糖蛋白介导的外排机制在肠道内被吸收。SOS1-IN-14 能够用于 KRAS 突变的癌症的研究，且抑瘤效果比 BI-3406 好。</p>Fórmula:C29H29F3N6O2Forma y color:SolidPeso molecular:550.57pan-KRAS-IN-4
CAS:<p>Pan-KRAS-IN-4 (compound 5) is a potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for Kras G12C and 0.19 nM for Kras G12V [1].</p>Fórmula:C36H34F2N6O3Pureza:98%Forma y color:SolidPeso molecular:636.69KRAS G12C inhibitor 51
CAS:<p>KRAS G12C inhibitor 51 is a KRAS G12C inhibitor.</p>Fórmula:C33H35FN6O3Forma y color:SolidPeso molecular:582.67KRAS G12D mutation regulator 4
CAS:<p>KRAS G12D mutation regulator 4 can be used in studies about Ras.</p>Fórmula:C33H33FN6O2Forma y color:SolidPeso molecular:564.65KRAS G12C inhibitor 21
CAS:<p>KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.</p>Fórmula:C34H30ClN3O4Forma y color:SolidPeso molecular:580.07CMP3a
CAS:<p>CMP3a, a NEK2 inhibitor, hinders GBM in mice and enhances radiotherapy by disrupting EZH2.</p>Fórmula:C28H27F3N6O2SForma y color:SolidPeso molecular:568.61Ras inhibitor 134
CAS:<p>Ras inhibitor 134 can be used in studies about Ras.</p>Fórmula:C23H21ClFN5O3Forma y color:SoildPeso molecular:469.9B-Raf IN 5
CAS:<p>B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR.</p>Fórmula:C23H18ClF3N6O3S2Forma y color:SolidPeso molecular:583.01HPK1-IN-10
CAS:<p>HPK1-IN-10 inhibits HPK1, a MAP4K kinase from progenitor cells, with potential in treating HPK1 diseases, detailed in patent WO2021213317A1.</p>Fórmula:C31H34N6O2Forma y color:SolidPeso molecular:522.64SOS1/KRAS-IN-1
CAS:<p>SOS1/KRAS-IN-1 (Compound 2) serves as an inhibitor of SOS1/KRAS, with potential application in the study of diseases mediated by SOS1/KRAS [1].</p>Fórmula:C24H26F3N5OPureza:98%Forma y color:SolidPeso molecular:457.49SOS1-IN-5
CAS:<p>SOS1-IN-5, a potent pyrimidine inhibitor, disrupts RAS-SOS1, blocking KRAS activation.</p>Fórmula:C26H31F3N4O5Forma y color:SolidPeso molecular:536.54GNE 220 hydrochloride
CAS:<p>GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Fórmula:C25H27ClN8Forma y color:SolidPeso molecular:474.99KRAS inhibitor-12
CAS:<p>KRAS inhibitor-12 blocks KRAS G12C (IC50: 0.537 μM) and p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancer study.</p>Fórmula:C19H16Cl2FN5OSForma y color:SolidPeso molecular:452.33SKF-86002 dihydrochloride
CAS:<p>p38 MAP kinase inhibitor</p>Fórmula:C16H14Cl2FN3SPureza:98%Forma y color:SolidPeso molecular:370.27K-Ras G12C-IN-1
CAS:<p>K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.</p>Fórmula:C22H23Cl2N3O3Forma y color:SolidPeso molecular:448.34KRAS G12C inhibitor 25
CAS:<p>KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).</p>Fórmula:C32H41N7O2Forma y color:SolidPeso molecular:555.71SOS1-IN-16
CAS:<p>SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 of</p>Fórmula:C30H31F3N4O3Pureza:98%Forma y color:SolidPeso molecular:552.59HPK1-IN-33
CAS:<p>HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.</p>Fórmula:C18H16ClFN6Forma y color:SolidPeso molecular:370.81KRAS G12C inhibitor 53
CAS:<p>KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.</p>Fórmula:C21H14ClF2N5O2Forma y color:SolidPeso molecular:441.82HPK1-IN-11
CAS:<p>HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.</p>Fórmula:C27H25N5O2Forma y color:SolidPeso molecular:451.52pan-KRAS-IN-3
CAS:<p>Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].</p>Fórmula:C33H32F3N5O2Pureza:98%Forma y color:SolidPeso molecular:587.63SB 203580 sulfone
CAS:<p>SB 203580 sulfone, an analog of the p38 MAP kinase inhibitor SB 203580, inhibits IL-1 production in monocytes and binds competitively with CSAID binding proteins (CSBP), inhibiting stress response signaling. It exhibits an IC50 of 0.2 μM for IL-1 inhibition and 0.03 μM for CSBP-mediated signaling inhibition [1].</p>Fórmula:C21H16FN3O2SForma y color:SolidPeso molecular:393.43AZ-TAK1
CAS:<p>"AZ-Tak1 inhibits TAK1 kinase (IC50=0.009mM), reduces p38/ERK levels, and induces apoptosis in Mino, SP53, Jeko cells with increasing efficacy at 0.1-0.5mM."</p>Fórmula:C25H28FN7O2Forma y color:SolidPeso molecular:477.53AMG-548 dihydrochloride (864249-60-5 free base)
<p>AMG-548 dihydrochloride: oral p38α inhibitor, Ki: 0.5 nM; less so for p38β, Ki: 36 nM; >> p38γ/δ; blocks LPS-induced TNFα, IC50: 3 nM.</p>Fórmula:C29H29Cl2N5OPureza:98%Forma y color:SolidPeso molecular:534.48HPK1-IN-35
CAS:<p>HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM.</p>Fórmula:C30H32N8O3SForma y color:SolidPeso molecular:584.69Rac1-IN-3
CAS:<p>Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].</p>Fórmula:C21H23N7O2Pureza:98%Forma y color:SolidPeso molecular:405.45BI-0474
CAS:<p>BI-0474: KRASG12C inhibitor, IC50=7.0 nM, blocks GDP-KRAS/SOS1, anti-tumor in NCI-H358 cells & lung cancer model, for cancer research.</p>Fórmula:C30H37N9O2SPureza:99.61%Forma y color:SolidPeso molecular:587.74FGTI-2734 mesylate (1247018-19-4 free base)
CAS:<p>FGTI-2734 mesylate hinders KRAS, overcoming resistance and targeting pancreatic tumors; inhibits FT and GGT with IC50s of 250 nM, 520 nM.</p>Fórmula:C27H35FN6O5S2Pureza:98%Forma y color:SolidPeso molecular:606.73(R)-VX-11e
CAS:<p>(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.</p>Fórmula:C24H20Cl2FN5O2Pureza:98.73%Forma y color:SolidPeso molecular:500.35ERK-IN-2 free base
CAS:<p>ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.</p>Fórmula:C16H17N5O2Forma y color:SolidPeso molecular:311.34KRAS G12C inhibitor 59
CAS:<p>KRAS G12C Inhibitor 59 is a compound with anticancer properties.</p>Fórmula:C32H39F6N7O5Pureza:98%Forma y color:SolidPeso molecular:715.69KRAS inhibitor FB9
CAS:<p>KRAS inhibitor FB9 can be used in studies about Ras.</p>Fórmula:C23H21ClF4N2O5Forma y color:SolidPeso molecular:516.87HPK1-IN-12
CAS:<p>HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Fórmula:C25H24FN5O2Forma y color:SolidPeso molecular:445.49KRAS G12C inhibitor 32
CAS:<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Fórmula:C29H30Cl3FN6O3Pureza:98%Forma y color:SolidPeso molecular:635.94DL-threo dihydrosphingosine
CAS:<p>DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.</p>Fórmula:C18H39NO2Forma y color:SolidPeso molecular:301.51MNK inhibitor 9
CAS:<p>MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.</p>Fórmula:C25H29N9OForma y color:SolidPeso molecular:471.56ERK1/2 inhibitor 7
CAS:<p>ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).</p>Fórmula:C23H22FN7OSForma y color:SolidPeso molecular:463.53KRAS inhibitor-11
<p>KRAS inhibitor-11 is a KRAS inhibitor .</p>Fórmula:C29H47N9O6Forma y color:SolidPeso molecular:617.74Inflachromene
CAS:<p>Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.</p>Fórmula:C21H19N3O4Pureza:97.36% - 99.88%Forma y color:SolidPeso molecular:377.39SOS1-IN-13
CAS:<p>SOS1-IN-13 inhibits SOS1 (IC50: 6.5 nM) and pERK (327 nM); potential in cancer research.</p>Fórmula:C21H22F3N3O2Forma y color:SolidPeso molecular:405.41KRAS G12C inhibitor 1R
CAS:<p>KRAS G12C inhibitor 1R can be used in studies about Ras.</p>Fórmula:C31H36ClFN6O2Forma y color:SoildPeso molecular:579.11Raf inhibitor 3
CAS:<p>Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].</p>Fórmula:C18H19FN8O2SPureza:98%Forma y color:SolidPeso molecular:430.46Laxiflorin B
CAS:<p>Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].</p>Fórmula:C20H24O5Pureza:98%Forma y color:SolidPeso molecular:344.4HPK1-IN-13
CAS:<p>HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Fórmula:C25H24FN5O2Forma y color:SolidPeso molecular:445.49GSK1790627
CAS:<p>GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].</p>Fórmula:C24H21FIN5O3Forma y color:SolidPeso molecular:573.36Glecirasib
CAS:<p>Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signaling</p>Fórmula:C31H26ClF4N7O2Pureza:99.7% - >99.99%Forma y color:SolidPeso molecular:640.03ZG1077
CAS:<p>ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.</p>Fórmula:C33H33F2N5O5SForma y color:SolidPeso molecular:649.71HPK1-IN-27
CAS:<p>HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.</p>Fórmula:C26H23F3N4O4Forma y color:SolidPeso molecular:512.48Org OD 02-0
CAS:<p>10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate</p>Fórmula:C22H30O2Pureza:98%Forma y color:SolidPeso molecular:326.47B-Raf IN 15
CAS:<p>B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.</p>Fórmula:C19H15N3OSPureza:98%Forma y color:SolidPeso molecular:333.41KRAS G12C inhibitor 61
CAS:<p>KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.</p>Fórmula:C31H33ClFN7O2Pureza:98%Forma y color:SolidPeso molecular:590.09ERK1/2 inhibitor 9
CAS:<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Fórmula:C31H32ClN7O3Pureza:98%Forma y color:SolidPeso molecular:586.08FGTI-2734
CAS:<p>FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.</p>Fórmula:C26H31FN6O2SPureza:99.69%Forma y color:SolidPeso molecular:510.63GNE 220
CAS:<p>GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Fórmula:C25H26N8Pureza:98%Forma y color:SolidPeso molecular:438.53XRP44X
CAS:<p>XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.</p>Fórmula:C21H21ClN4OPureza:99.67%Forma y color:SolidPeso molecular:380.87DT-061
CAS:<p>DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.</p>Fórmula:C25H23F3N2O5SPureza:98%Forma y color:SolidPeso molecular:520.52KRAS G12C inhibitor 16
CAS:<p>KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.</p>Fórmula:C24H21ClFN3O3Pureza:97.84%Forma y color:SolidPeso molecular:453.89CXJ-2
CAS:<p>CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.</p>Fórmula:C55H87N15O22Pureza:98%Forma y color:SolidPeso molecular:1310.37KRAS G12C inhibitor 58
CAS:<p>KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].</p>Fórmula:C51H64ClF4N9O8SPureza:98%Forma y color:SolidPeso molecular:1074.62KRAS degrader-1
CAS:<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Fórmula:C55H57Br2ClFIN8O7Forma y color:SolidPeso molecular:1283.25KRAS G12D modulator-1
CAS:<p>KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and is</p>Fórmula:C30H36FN5O4Pureza:98%Forma y color:SolidPeso molecular:549.64Ilaprazole sodium hydrate
CAS:<p>Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.</p>Fórmula:C19H21N4NaO4SPureza:99.2%Forma y color:SolidPeso molecular:424.45pan-KRAS-IN-2
CAS:<p>Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D</p>Fórmula:C34H34F2N4O3Pureza:98%Forma y color:SolidPeso molecular:584.66SB-682330A
CAS:<p>SB-682330A is a Raf kinase inhibitor.</p>Fórmula:C28H27N3O3Forma y color:SolidPeso molecular:453.53TC13172
CAS:<p>TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.</p>Fórmula:C17H16N4O5SPureza:98%Forma y color:SolidPeso molecular:388.4Kras binder 12
CAS:<p>Kras binder 12 can be used in studies about Ras.</p>Fórmula:C29H47N9O6Forma y color:SoildPeso molecular:617.74Cobimetinib racemate
CAS:<p>Cobimetinib racemate (Cobimetinib (racemate)) (GDC-0973 racemate) is a selective inhibitor of MEK.Cobimetinib racemate is also known as a mitogen-activated</p>Fórmula:C21H21F3IN3O2Pureza:98.00% - 99.71%Forma y color:SolidPeso molecular:531.31SHP2-IN-22
CAS:<p>SHP2-IN-22, a potent SHP2 allosteric inhibitor, exhibits an IC50 value of 17.7 nM and effectively suppresses proliferation, migration, and invasion in MIA PaCa-</p>Fórmula:C23H22Cl2N8OForma y color:SolidPeso molecular:497.38ARQ-736
CAS:<p>ARQ 736 effectively targets and inhibits BRAF, crucial in MAPK pathway, beneficial for treating melanomas and certain colon cancers.</p>Fórmula:C25H25N8Na2O8PSForma y color:SolidPeso molecular:674.54B-Raf IN 16
CAS:<p>B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.</p>Fórmula:C20H19N5O3SPureza:99.31% - 99.78%Forma y color:SolidPeso molecular:409.46KRAS G12C inhibitor 17
CAS:<p>KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.</p>Fórmula:C24H20ClF2N3O3Pureza:98%Forma y color:SolidPeso molecular:471.88ARS-1323-alkyne
CAS:ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.Fórmula:C28H27ClF2N6O3Pureza:98.00% - 99%Forma y color:SolidPeso molecular:569ERK1/2 inhibitor 5
CAS:<p>ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.</p>Fórmula:C28H32ClFN6O5Forma y color:SolidPeso molecular:587.04KRAS inhibitor-18
CAS:<p>KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.</p>Fórmula:C20H15ClF3N3O2SForma y color:SolidPeso molecular:453.87ARS-1323
CAS:<p>ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.</p>Fórmula:C21H17ClF2N4O2Pureza:99.53%Forma y color:SolidPeso molecular:430.84HPK1 antagonist-1
CAS:<p>HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].</p>Fórmula:C28H29FN6O2Forma y color:SolidPeso molecular:500.57TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Fórmula:C30H38N6OPureza:98%Forma y color:SolidPeso molecular:498.66HPK1-IN-9
CAS:<p>HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)</p>Fórmula:C30H33N7O2Forma y color:SolidPeso molecular:523.63Uplarafenib
CAS:<p>Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.</p>Fórmula:C22H21F3N4O4SPureza:99.85%Forma y color:SolidPeso molecular:494.49KRAS G12C inhibitor 28
CAS:<p>KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (</p>Fórmula:C33H36F2N5O4PForma y color:SolidPeso molecular:635.64K-Ras G12C-IN-2
CAS:<p>K-Ras G12C-IN-2 is a covalent kras g12c inhibitor.</p>Fórmula:C21H27ClN4O3Pureza:98%Forma y color:SolidPeso molecular:418.92CHI-000-667
CAS:<p>CHI-000-667 can be used in studies about Ras.</p>Fórmula:C21H16ClNO4SForma y color:SolidPeso molecular:413.87KRAS G12C inhibitor 40
CAS:<p>KRAS G12C inhibitor 40 targets KRAS G12C in cancer research (WO2021129824A1, compound 70).</p>Fórmula:C34H36ClFN10O2Forma y color:SolidPeso molecular:671.17KRAS G12C inhibitor 49
CAS:<p>KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.</p>Fórmula:C31H31ClN6O3Forma y color:SolidPeso molecular:571.07JWG-071
CAS:<p>JWG-071: First ERK5 kinase probe, BET inhibitor, 1 μM BRD4 IC, boosts ERK5 function and BRD4 selectivity.</p>Fórmula:C34H44N8O3Pureza:98.33%Forma y color:SolidPeso molecular:612.77ZYF0033
CAS:<p>ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.</p>Fórmula:C26H30N4O2SPureza:99.70%Forma y color:SolidPeso molecular:462.61Exarafenib
CAS:<p>Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.</p>Fórmula:C26H34F3N5O3Pureza:98.36% - 99.84%Forma y color:SolidPeso molecular:521.58HG6-64-1
CAS:<p>HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.</p>Fórmula:C32H34F3N5O2Pureza:99.89%Forma y color:SolidPeso molecular:577.64Kras4B G12D-IN-1
CAS:<p>Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.</p>Fórmula:C16H21ClN2O4SPureza:99.75%Forma y color:SolidPeso molecular:372.87BI-2493
CAS:<p>BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.</p>Fórmula:C24H27N7OSPureza:97.74% - 99.88%Forma y color:SoildPeso molecular:461.58MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Fórmula:C37H41N9O3SPureza:96.15% - 97.19%Forma y color:SolidPeso molecular:691.84Pan-RAS-IN-1
CAS:<p>Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.</p>Fórmula:C36H41Cl2F3N6O2Pureza:99.77%Forma y color:SolidPeso molecular:717.65KRAS inhibitor-8
CAS:<p>KRAS inhibitor-8 is a potent KRAS G12C inhibitor.</p>Fórmula:C26H24ClF4N5O3Pureza:98%Forma y color:SolidPeso molecular:565.95MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Fórmula:C25H24N4O2Forma y color:SolidPeso molecular:412.48KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Fórmula:C14H13NO4Forma y color:SolidPeso molecular:259.26KRASG12C IN-12
CAS:<p>KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.</p>Fórmula:C29H39N5O6S2Forma y color:SolidPeso molecular:617.78KRAS G12D inhibitor 19
CAS:<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>Fórmula:C35H34F2N6O3Forma y color:SolidPeso molecular:624.68KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Fórmula:C24H28F3N5Forma y color:SolidPeso molecular:443.51PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Fórmula:C45H68N4OForma y color:SolidPeso molecular:681.05AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Fórmula:C24H21ClF2N4O3Forma y color:SolidPeso molecular:486.9Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Fórmula:C32H31ClF2N6O4Pureza:98.69%Forma y color:SolidPeso molecular:637.08BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Fórmula:C35H33F6N7O2SPureza:97.879%Forma y color:SolidPeso molecular:729.74KRAS G12C inhibitor 46
CAS:<p>KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.</p>Fórmula:C32H33F2N7O2Forma y color:SolidPeso molecular:585.65KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Fórmula:C38H32F4N6O3SForma y color:SolidPeso molecular:728.76COTI-219
CAS:<p>COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].</p>Fórmula:C17H18N6SForma y color:SolidPeso molecular:338.43pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Fórmula:C29H30ClF3N6O3SForma y color:SolidPeso molecular:635.10KRASG12D-IN-3-d3
CAS:KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.Fórmula:C31H27D3ClF6N7O2Forma y color:SoildPeso molecular:685.08KRAS inhibitor-21
CAS:<p>KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.</p>Fórmula:C33H41N5O3Forma y color:SolidPeso molecular:555.71Famlasertib
CAS:<p>Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.</p>Fórmula:C26H27ClN4OForma y color:SolidPeso molecular:446.972Everafenib
<p>Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.</p>Fórmula:C20H23ClFN5O2S2Forma y color:SolidPeso molecular:484.01TH-Z816
CAS:<p>TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].</p>Fórmula:C29H38N6OForma y color:SolidPeso molecular:486.65HPK1-IN-41
CAS:<p>HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].</p>Fórmula:C28H33N5O2Forma y color:SolidPeso molecular:471.59(+)-Perillyl alcohol
CAS:<p>(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.</p>Fórmula:C10H16OForma y color:SolidPeso molecular:152.23G12Si-1
<p>G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.</p>Fórmula:C29H32ClN5O3Forma y color:SolidPeso molecular:534.05MAP855
CAS:<p>MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.</p>Fórmula:C28H23ClF2N6O3Forma y color:SolidPeso molecular:564.97MBA-m1
CAS:<p>MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.</p>Fórmula:C27H21ClN2O2Forma y color:SolidPeso molecular:440.92ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Fórmula:C24H18N2O7S2Forma y color:SolidPeso molecular:510.539JD123
CAS:<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>Fórmula:C12H11N5S2Forma y color:SolidPeso molecular:289.379KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Fórmula:C35H32Cl2FN5OForma y color:SolidPeso molecular:628.57MLKL-IN-1
<p>MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.</p>Fórmula:C19H20N2O3Forma y color:SolidPeso molecular:324.37INCB159020
CAS:<p>INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.</p>Fórmula:C37H35ClFN7O2Forma y color:SolidPeso molecular:664.171GDC-6036-NH
CAS:<p>GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.</p>Fórmula:C26H30ClF4N7OPureza:99.84%Forma y color:SolidPeso molecular:568.01KRAS inhibitor-13
CAS:<p>KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.</p>Fórmula:C25H19ClFN3O2SForma y color:SolidPeso molecular:479.95HPK1-IN-42
CAS:<p>HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].</p>Fórmula:C26H30N6OSForma y color:SolidPeso molecular:474.62AMG-548 hydrochloride
<p>AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.</p>Fórmula:C29H28ClN5OForma y color:SolidPeso molecular:498.02SHR902275
CAS:<p>SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.</p>Fórmula:C26H23F3N4O4Forma y color:SolidPeso molecular:512.48ERK1/2 inhibitor 6
CAS:<p>ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.</p>Fórmula:C27H29ClFN7O5Forma y color:SolidPeso molecular:586.01RSK4-IN-1
CAS:<p>RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.</p>Fórmula:C19H20F2N4O3Forma y color:SolidPeso molecular:390.38HPK1-IN-3
<p>HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.</p>Fórmula:C23H22F4N6O2Forma y color:SolidPeso molecular:490.45SOS1-IN-9
<p>SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).</p>Fórmula:C22H28F3N5OForma y color:SolidPeso molecular:435.49KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Fórmula:C30H37FN10OSForma y color:SolidPeso molecular:604.745KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Fórmula:C31H36ClFN6O2Forma y color:SolidPeso molecular:579.11Rho GTPase inhibitor 1
CAS:<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Fórmula:C18H16N2OForma y color:SolidPeso molecular:276.33MEK4 inhibitor-2
CAS:<p>MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.</p>Fórmula:C20H15FN4O3SForma y color:SolidPeso molecular:410.42EBI-907
CAS:<p>EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.</p>Fórmula:C23H21ClF2N4O3SForma y color:SolidPeso molecular:506.95LSN3074753
CAS:<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Fórmula:C24H30FN5O2Forma y color:SolidPeso molecular:439.53L 739749
CAS:<p>L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.</p>Fórmula:C24H41N3O6S2Pureza:98%Forma y color:SolidPeso molecular:531.73Fulzerasib
CAS:<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Fórmula:C32H30ClFN6O4Pureza:98.04%Forma y color:SolidPeso molecular:617.07SOS1-IN-6
CAS:<p>SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).</p>Fórmula:C26H28F3N3O2Forma y color:SolidPeso molecular:471.51HPK1-IN-21
<p>HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.</p>Fórmula:C22H25ClFN5O2Forma y color:SolidPeso molecular:445.92Cot inhibitor-3
CAS:<p>Cot inhibitor-3 (Compound 33) is an effective and selective cancerosaka thyroid (COT) kinase inhibitor with an IC50 of 4 nM. It can be used to prevent limpness caused by inflammation.</p>Fórmula:C30H28N8OForma y color:SolidPeso molecular:516.60MEK1/2-IN-2
<p>MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.</p>Fórmula:C28H22ClFN6OForma y color:SolidPeso molecular:512.97BMS-214662
CAS:<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Fórmula:C25H23N5O2S2Pureza:99.58% - 99.58%Forma y color:SolidPeso molecular:489.61HPK1-IN-16
CAS:<p>HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.</p>Fórmula:C28H27FN4OForma y color:SolidPeso molecular:454.54HPK1-IN-31
<p>HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .</p>Fórmula:C30H33N7O3Forma y color:SolidPeso molecular:539.63AMG-548 dihydrochloride
<p>AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.</p>Fórmula:C29H29Cl2N5OForma y color:SolidPeso molecular:534.48K-Ras-IN-4
CAS:<p>K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.</p>Fórmula:C31H28F4N6O3SForma y color:SolidPeso molecular:640.65ERK2 IN-1
CAS:<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Fórmula:C36H34FN7O2SPureza:98%Forma y color:SolidPeso molecular:647.76HPK1-IN-30
CAS:<p>HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.</p>Fórmula:C25H23FN6Forma y color:SolidPeso molecular:426.49ATX inhibitor 26
CAS:<p>ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.</p>Fórmula:C18H19Cl2N7O3Forma y color:SolidPeso molecular:452.30VVD-699
CAS:<p>VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.</p>Fórmula:C25H30ClFN2O6S2Forma y color:SolidPeso molecular:573.097MCB-22-174
CAS:MCB-22-174 is a potent agonist of Piezo1 with an EC50 value of 6.28 µM. It activates Ca2+-related extracellular signal-regulated kinase and calcium-calmodulin (CaM)-dependent protein kinase II (CaMKII) pathways, and it promotes mesenchymal stem cell osteogenic differentiation, indicating its potential application in the study of disuse osteoporosis (OP).Fórmula:C16H14DCl2N5OS2Peso molecular:429.37SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Fórmula:C23H22ClN7O2Forma y color:SolidPeso molecular:463.92HPK1-IN-55
CAS:<p>HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.</p>Fórmula:C30H34N8O3Forma y color:SolidPeso molecular:554.643KRAS G12C inhibitor 50
CAS:<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Fórmula:C31H34N8O2Forma y color:SolidPeso molecular:550.65KRAS G12D inhibitor 3
CAS:<p>KRAS G12D Inhibitor 3, a compound targeting the KRAS G12D mutation, demonstrates potent antitumor efficacy with an inhibitory concentration (IC50) of less than</p>Fórmula:C34H31ClF3N5O2Forma y color:SolidPeso molecular:634.09Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Fórmula:C36H39ClFN7O4Forma y color:SolidPeso molecular:688.191MRTX849 ethoxypropanoic acid
CAS:<p>MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.</p>Fórmula:C37H43ClFN7O5Forma y color:SolidPeso molecular:720.24KRAS G12D inhibitor 12
<p>KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)</p>Fórmula:C23H21ClFN5O3Forma y color:SolidPeso molecular:469.9ERK-IN-2
CAS:<p>ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].</p>Fórmula:C16H18ClN5O2Pureza:98%Forma y color:SolidPeso molecular:347.80SML-10-70-1
CAS:<p>SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.</p>Fórmula:C25H42ClN7O13P2Forma y color:SolidPeso molecular:746.04Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Fórmula:C27H41NO8Forma y color:SolidPeso molecular:507.616SOF-436
CAS:<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Fórmula:C15H13F2NO4S2Forma y color:SolidPeso molecular:373.395
